CSL Behring Awards advocacy grants to patient groups in Maryland, New England, the Midwest and Washington
CSL Behring, a global leader in the plasma protein biotherapies industry and a subsidiary of CSL Limited (ASX:CSL), has awarded advocacy grants totaling almost $100,000 to six patient organizations through the Local Empowerment for Advocacy Development (LEAD) program. LEAD grants support the grassroots advocacy efforts of organizations committed to helping people who use plasma-derived or recombinant therapies to manage rare and serious diseases.
'CSL Behring is pleased to recognize and support these organizations, all of which play a vital role in expanding patient access to information and healthcare,' said Dennis Jackman, Senior Vice President, Public Affairs, CSL Behring. 'We hope these grants will help improve the lives of people with bleeding disorders, immune deficiencies and hereditary angioedema.'
The following organizations were awarded CSL Behring LEAD grants:
The Hemophilia Foundation of Maryland (HFM), Parkville, MD
HFM received a LEAD grant from CSL Behring to support its legislative initiatives for Maryland Bleeding Disorders Standards of Care. The Foundation is looking to build upon its success from the previous legislative session when the bill was first introduced.
'In 2010 our small but proactive bleeding disorders community championed the introduction of the Hemophilia Standards of Care Act (Health Insurance Coverage for the Treatment of Bleeding Disorders),' said Executive Director Emma Miller-Clark. 'The LEAD grant will enable us to pick up where we left off in 2010 and provide funding to continue HFM Maryland Days and educate future advocates. Thank you CSL Behring for bringing us one step closer to passage of the Hemophilia Standards of Care Act!'
The Bleeding Disorder Foundation of Washington (BDFW), Edmonds, WA
LEAD grant funds to BDFW will be used to support its state advocacy day in Olympia, WA and to increase participation from the eastern part of the state.
'The Foundation is thrilled to be awarded a CSL Behring LEAD Grant. It is this kind of dedication that CSL Behring provides back to the bleeding disorder community that allows chapters like ours to provide excellent care and service to our community,' Kristian Prill, Executive Director said. 'The funding being provided will allow us to increase education and advocacy for bleeding disorders and healthcare reform at a critical time in the process.'
The Immune Deficiency Foundation (IDF), Towson, MD
IDF will use its LEAD grant to support Capitol Hill Day where individuals with primary immune deficiencies and their families travel to Washington, DC to meet with their legislators and discuss issues impacting this community. In addition to Capitol Hill Day, the IDF will also jointly conduct a Raise Your Voice! program with CSL Behring. Raise Your Voice! helps teenagers become active advocates and is part of the CSL Behring LEAD program.
'The IDF thanks CSL Behring for the LEAD grant and for letting the voices of those with primary immunodeficiencies be heard,' Lawrence A. LaMotte, Director Public Policy, IDF, said.
The New England Hemophilia Association (NEHA), Dedham, MA
NEHA will use the grant from CSL Behring to expand its consumer network and to train volunteers. In addition, the LEAD grant will provide staffing resources to help drive NEHA's advocacy priorities through legislation and coalition building.
'NEHA is grateful to receive a LEAD grant from CSL Behring in support of our Advocacy program. Promoting the needs of the bleeding disorders community in our six-state area presents many challenges. We look forward to working with CSL Behring to serve our community,' said Kevin R. Sorge, Executive Director, NEHA.
The Midwest Hemophilia Association (MHA), Kansas City, MO
MHA will use its LEAD grant to bolster legislative efforts in support of passage of Standards of Care for People with Bleeding Disorders in Missouri. In addition, MHA will start grassroots advocacy in Kansas and also help educate the public about women's bleeding disorders.
'MHA is delighted to receive this generous LEAD grant from CSL Behring. This grant will help our ultimate goal to make all our members better self-advocates,' Kristin Marema, MHA Board Member, said.
The Hereditary Angioedema Association (HAEA), Honolulu, HI
The HAEA will use its LEAD grant funds to support the establishment of a public policy program. Already, the HAEA held its first federal advocacy day where select volunteers traveled to Washington to inform their legislators about hereditary angioedema and the need for increased research into this potentially life-threatening condition.
'The Association is passionate about making a better life for all HAE patients and is grateful for the opportunity to advocate for HAE research on a federal level,' said Janet F. Long, Executive Vice President of the US HAEA.
LEAD Grant Application Deadline
LEAD grants are awarded semi-annually. CSL Behring considers grant proposals which relate to bleeding and platelet disorders, immune deficiencies, pulmonary disease and critical care. The submission deadline for the next round of grants is April 30, 2011. Applications, specific criteria for applying and more information about the LEAD program are available at www.cslbehring.com/leadgrants.
About CSL Behring
CSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide.
CSL Behring therapies are indicated for the treatment of coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in newborns.
CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. CSL Behring is a subsidiary of CSL Limited (ASX:CSL), a biopharmaceutical company headquartered in Melbourne, Australia. For more information, visit www.cslbehring.com.
Related news
-
Artugen Announces Five Abstracts Published in the 30th ECCMID Abstract Book
Clostridioides difficile infection (CDI) causes the most common healthcare-associated infections in the United States and the most frequent hospital-acquired intestinal infection in Europe and worldwide. The prevalence of C. difficile outbreaks since the early 2000s has resulted in higher morbidity and mortality along with increasing medical costs throughout the world. Without effective antibiotics and therapeutics for the prevention and treatment of infections, many of the achievements of modern medicine such...
-
Diaphragm Pacemaker for Teen Featured on WSB-TV Atlanta
Fourteen year-old Sedarius was recently featured on WSB-TV Atlanta as the first pediatric patient to receive surgery to implant a diaphragm pacemaker in the state of Georgia. Sedarius was diagnosed with CCHS when he was eight years old, and required a tracheotomy and ventilator to breathe while he slept. The Avery Breathing Pacemaker will allow him to breathe without the need for a trach or ventilator and help improve his quality of life. He was able to return home within a few days, and it is expected that he...
-
Christie Medical Holdings, Inc. Partners with DO-PA A.S. for Turkey Distribution
As the leader in vein visualization technology throughout the world, Christie’s high-quality, made-in-the USA, VeinViewer®Vision2 and VeinViewer® Flex, continue to provide customers with improved clinical outcomes such as increasing 1st stick success, decreasing medically not required PICC lines and enhancing patient satisfaction. We are committed to the continued growth of VeinViewer® as a standard of care and are excited to partner with DO-PA Inc. as our authorized distributor for Turkey.DO-PA...
-
Outlook on the Medical Ceramics Global Market to 2026 - Identify Key Drivers and Challenges
According to Fast. MR research the report titled Global Medical Ceramics Market provides comprehensive information regarding influential factors. Data included in the report has been curated by our team of industry experts, considering relevant information about the market. This report discusses the growth and trends of various regions and segments of the market. Information such as market drivers, restraints, opportunities, trends, gross revenue, average product/service price, and market share of major players...
-
BlueRock Therapeutics Announces First Patient Dosed with DA01 in Phase 1 Study in Patients with Advanced Parkinson`s Disease
BlueRock Therapeutics, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, announced today the dose administration for the first patient in a Phase 1 (Ph1), open-label study of pluripotent stem cell-derived dopaminergic neurons in patients with advanced Parkinson’s disease (PD). The purpose of the Ph1 clinical trial is to evaluate the safety, tolerability, and preliminary efficacy of DA01 in patients with PD. “It’s both exciting and humbling to be a part of...
Customer comments
No comments were found for CSL Behring Awards advocacy grants to patient groups in Maryland, New England, the Midwest and Washington. Be the first to comment!